These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 32975737)

  • 1. High-Efficacy Disease-Modifying Therapies in People with Relapsing-Remitting Multiple Sclerosis: The Role of Risk Attitude in Treatment Decisions.
    Maurino J; Sotoca J; Sempere ÁP; Brieva L; López de Silanes C; Caminero AB; Terzaghi M; Gracia-Gil J; Saposnik G
    Patient; 2021 Mar; 14(2):241-248. PubMed ID: 32975737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient perspective on decisions to switch disease-modifying treatments in relapsing-remitting multiple sclerosis.
    Manzano A; Eskyté I; Ford HL; Pavitt SH; Potrata B; Schmierer K; Chataway J; Webb EJD; Meads D; Pepper G; Bekker HL
    Mult Scler Relat Disord; 2020 Nov; 46():102507. PubMed ID: 32979733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decision Making About Disease-Modifying Treatments for Relapsing-Remitting Multiple Sclerosis: Stated Preferences and Real-World Choices.
    Webb EJD; Meads D; Eskytė I; Ford HL; Bekker HL; Chataway J; Pepper G; Marti J; Okan Y; Pavitt SH; Schmierer K; Manzano A
    Patient; 2023 Sep; 16(5):457-471. PubMed ID: 37072663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlates and trajectories of relapses in relapsing-remitting multiple sclerosis.
    Young CA; Rog DJ; Sharrack B; Tanasescu R; Kalra S; Harrower T; Tennant A; Mills RJ;
    Neurol Sci; 2024 May; 45(5):2181-2189. PubMed ID: 37976012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delayed cognitive processing and treatment status quo bias in early-stage multiple sclerosis.
    Saposnik G; Andhavarapu S; Sainz de la Maza S; Castillo-Triviño T; Borges M; Barón BP; Sotoca J; Alonso A; Caminero AB; Borrega L; Sánchez-Menoyo JL; Barrero-Hernández FJ; Calles C; Brieva L; Blasco MR; García-Soto JD; Del Campo-Amigo M; Navarro-Cantó L; Agüera E; Garcés M; Carmona O; Gabaldón-Torres L; Forero L; Hervás M; García-Arcelay E; Terzaghi M; Gómez-Ballesteros R; Maurino J
    Mult Scler Relat Disord; 2022 Dec; 68():104138. PubMed ID: 36029707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Socioeconomic status and disease-modifying therapy prescribing patterns in people with multiple sclerosis.
    Reyes S; Suarez S; Allen-Philbey K; Yildiz Ö; Mathews J; Anjorin G; Edwards F; Jain C; Turner B; Marta M; Gnanapavan S; Schmierer K; Giovannoni G
    Mult Scler Relat Disord; 2020 Jun; 41():102024. PubMed ID: 32143179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial.
    Burt RK; Balabanov R; Burman J; Sharrack B; Snowden JA; Oliveira MC; Fagius J; Rose J; Nelson F; Barreira AA; Carlson K; Han X; Moraes D; Morgan A; Quigley K; Yaung K; Buckley R; Alldredge C; Clendenan A; Calvario MA; Henry J; Jovanovic B; Helenowski IB
    JAMA; 2019 Jan; 321(2):165-174. PubMed ID: 30644983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age and sex as determinants of treatment decisions in patients with relapsing-remitting MS.
    Sorensen PS; Kopp TI; Joensen H; Olsson A; Sellebjerg F; Magyari M
    Mult Scler Relat Disord; 2021 May; 50():102813. PubMed ID: 33578207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
    Foo EC; Russell M; Lily O; Ford HL
    Mult Scler Relat Disord; 2020 Sep; 44():102330. PubMed ID: 32599468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding treatment decisions from the perspective of people with relapsing remitting multiple Sclerosis: A critical interpretive synthesis.
    Eskyte I; Manzano A; Pepper G; Pavitt S; Ford H; Bekker H; Chataway J; Schmierer K; Meads D; Webb E; Potrata B
    Mult Scler Relat Disord; 2019 Jan; 27():370-377. PubMed ID: 30476873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decisional Conflict Regarding Disease-Modifying Treatment Choices Among Patients with Mid-Stage Relapsing-Remitting Multiple Sclerosis.
    Sabin J; Salas E; Martín-Martínez J; Candeliere-Merlicco A; Barrero Hernández FJ; Alonso Torres AM; Sánchez-Menoyo JL; Borrega L; Rodríguez-Rodríguez M; Gómez-Gutiérrez M; Eichau S; Hernández-Pérez MÁ; Calles C; Fernandez-Diaz E; Carmona O; Orviz A; López-Real A; López-Muñoz P; Mendoza Rodríguez A; Aguera-Morales E; Maurino J
    Patient Prefer Adherence; 2024; 18():1163-1171. PubMed ID: 38863945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes.
    Yano H; Gonzalez C; Healy BC; Glanz BI; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2019 Oct; 35():119-127. PubMed ID: 31374460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of Reproductive Issues on Preferences of Women with Relapsing Multiple Sclerosis for Disease-Modifying Treatments.
    Webb EJD; Meads D; Eskytė I; Ford HL; Bekker HL; Chataway J; Pepper G; Marti J; Okan Y; Pavitt SH; Schmierer K; Manzano A
    Patient; 2020 Oct; 13(5):583-597. PubMed ID: 32588337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of communication on first treatment decisions in people with relapsing-remitting multiple sclerosis.
    Manzano A; Eskytė I; Ford HL; Bekker HL; Potrata B; Chataway J; Schmierer K; Pepper G; Meads D; Webb EJ; Pavitt SH
    Patient Educ Couns; 2020 May; ():. PubMed ID: 32456983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic status quo in patients with relapsing-remitting multiple sclerosis: A sign of poor self-perception of their clinical status?
    Saposnik G; Sotoca J; Sempere ÁP; Candeliere-Merlicco A; Díaz-Abós P; Tobler PN; Terzaghi M; Maurino J
    Mult Scler Relat Disord; 2020 Oct; 45():102354. PubMed ID: 32629401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors influencing patients' willingness-to-pay for disease-modifying therapies for multiple sclerosis.
    Poudel N; Banjara B; Kamau S; Frost N; Ngorsuraches S
    Mult Scler Relat Disord; 2021 Feb; 48():102720. PubMed ID: 33429304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Framework for personalized prediction of treatment response in relapsing remitting multiple sclerosis.
    Stühler E; Braune S; Lionetto F; Heer Y; Jules E; Westermann C; Bergmann A; van Hövell P;
    BMC Med Res Methodol; 2020 Feb; 20(1):24. PubMed ID: 32028898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No evidence of disease activity-3 (NEDA-3) status in patients with relapsing remitting multiple sclerosis: Evidence from Saudi cohort receiving mainly Interferon.
    Zafar A; AlShamrani FJG
    Mult Scler Relat Disord; 2021 Jun; 51():102875. PubMed ID: 33691260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.